Sedation Management for Infants with Congenital Cardiac Disease

Introduction to Sedation Alternatives

The European Society of Cardiology recommends adding propofol as a second agent for sedation in mechanically ventilated infants with congenital cardiac disease who are not adequately sedated on fentanyl, providing rapid sedation with a short half-life 1, 2
Dexmedetomidine is an alternative sedative that may be particularly useful in cardiac patients, as it provides sedation with minimal respiratory depression, though it requires careful monitoring for bradycardia 1, 2

For propofol, the European Society of Cardiology suggests starting at the lower end of the dosing range (20 μg/kg/min) due to the cardiac condition, and titrating carefully while monitoring hemodynamics 2
The European Society of Cardiology recommends monitoring for hypotension, which is more common with propofol, and being vigilant for signs of inadequate sedation, including tachycardia, ventilator dyssynchrony, and movement or agitation 1, 2
The Society of Pediatric Anesthesia recommends reassessing sedation level 15-30 minutes after any medication change, and monitoring vital signs every 5 minutes during initial titration of a new agent 4

The European Society of Cardiology advises avoiding agents that might cause significant bradycardia in patients with congenital cardiac disease, and carefully titrating sedatives to maintain hemodynamic stability 2, 3
The European Society of Intensive Care Medicine recommends ensuring adequate ventilation parameters are maintained as sedation is adjusted, to prevent respiratory complications 4

The European Society of Cardiology warns against excessive sedation, which can lead to prolonged mechanical ventilation and delayed recovery, and recommends avoiding continuous benzodiazepine infusions due to the risk of delirium and prolonged sedation 1, 2
The European Society of Cardiology advises monitoring for propofol infusion syndrome, particularly with prolonged use or high doses in infants, and being aware of the risk of drug accumulation due to immature metabolism 2, 3